November 18, 2025 — Leads & Copy — FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D0) has signed a Memorandum of Understanding (MOU) with Aquaox LLC to develop eco-friendly pathogen-eliminating agents.
The MOU, dated November 17, 2025, outlines the intention of FendX and Aquaox to negotiate a collaboration and supply agreement to create advanced formulations for cleaning and disinfectant products aimed at healthcare, consumer, and commercial markets.
According to Dr. Carolyn Myers, CEO of FendX, this collaboration is a crucial advancement for FendX, enabling expansion into the disinfectant and cleaning market, which will complement the company’s existing surface protection technologies and support its goal of reducing pathogen transmission. She added that working with Aquaox will combine their expertise in disinfection, formulation, and manufacturing with FendX’s product development capabilities, delivering practical and effective hygiene solutions.
Michel van Schaik, CEO of Aquaox, stated that partnering with FendX aligns with their mission and track record in sustainable disinfection. He sees the MOU as an opportunity to extend their momentum by partnering with FendX to pioneer innovative, green technologies.
Under the definitive agreement, FendX and Aquaox will collaborate to develop advanced formulations of eco-friendly pathogen-eliminating agents. Aquaox will oversee the development and maintenance of the equipment required to produce and supply these agents to FendX, who will use them to develop cleaning and disinfectant products of its choosing. Any products developed by FendX, along with any new intellectual property, will be owned by FendX. Aquaox will own of all new EPA certifications granted for the agents and provide FendX access to these certifications.
The completion of the Definitive Agreement is contingent upon due diligence by both parties and the receipt of corporate and regulatory approvals, including that of the CSE. The MOU is valid for 12 months unless extended or terminated with 30 day’s written notice, or superseded by the Definitive Agreement.
FendX is focused on creating innovative solutions to reduce the spread of harmful pathogens, advancing a portfolio of protective surface coatings, including REPELWRAP™ film, a liquid-based nano-coating technology, and a specialized Foley catheter coating. The company is committed to building a robust intellectual property portfolio in the surface protection space and is focused on advancing new technologies and materials that enhance hygiene and safety across healthcare, consumer and commercial settings.
Aquaox LLC specializes in hypochlorous acid (HOCl) technologies and has commercialized its HOCl-based compounds through strategic partnerships across healthcare, commercial, and industrial sectors. Aquaox is committed to delivering safe, sustainable alternatives to conventional chemical disinfectants.
Carolyn Myers, Chief Executive Officer and Director
Investor Relations Phone: 1-800-344-9868 Email: investor@fendxtech.com
Source: FendX Technologies Inc.
Source: FendX Technologies Inc.
